Hepatocellular Carcinoma Tumor Immune Microenvironment

DAY 1

New York: Friday, December 4 • 6:00-9:15 PM
Honolulu: Friday, December 4 • 1:00-4:15 PM
Beijing, Hong Kong, Singapore, & Taipei: Saturday, December 5 • 7:00-10:15 AM
Seoul & Tokyo: Saturday, December 5 • 8:00-11:15 AM

DAY 2

New York: Saturday, December 5 • 6:00-9:15 PM
Honolulu: Saturday, December 5 • 1:00-4:15 PM
Beijing, Hong Kong, Singapore, & Taipei: Sunday, December 6 • 7:00-10:15 AM
Seoul & Tokyo: Sunday, December 6 • 8:00-11:15 AM
This Memorial Sloan Kettering Cancer Center (MSK) virtual conference is hosted in collaboration with the University of Hawaii (UH) and endorsed by the Asian Pacific Primary Liver Cancer Expert Association (APPLE).

This is a single topic conference focused on the Hepatocellular Carcinoma Tumor Immune Microenvironment and the use of checkpoint inhibitors in combination with other therapies including anti-angiogenics, tyrosine kinase inhibitors, other checkpoint inhibitors, plus other local therapies. This conference is intended for medical oncologists, hepatologists, gastroenterologists, interventional radiologists, surgeons, radiation oncologists, immunologists, basic science experts, plus all colleagues with an interest in Hepatocellular Carcinoma and Immunotherapy.

Memorial Sloan Kettering and the University of Hawaii are excited to host the first single topic conference albeit virtually, and honored to welcome APPLE on the other side of the Pacific!

**DAY 1**

**New York**
Friday, December 4 • 6:00-9:15 PM

**Honolulu**
Friday, December 4 • 1:00-4:15 PM

**Beijing, Hong Kong, Singapore, & Taipei**
Saturday, December 5 • 7:00-10:15 AM

**Seoul & Tokyo**
Saturday, December 5 • 8:00-11:15 AM

**DAY 2**

**New York**
Saturday, December 5 • 6:00-9:15 PM

**Honolulu**
Saturday, December 5 • 1:00-4:15 PM

**Beijing, Hong Kong, Singapore, & Taipei**
Sunday, December 6 • 7:00-10:15 AM

**Seoul & Tokyo**
Sunday, December 6 • 8:00-11:15 AM

**COURSE DIRECTORS**

**Ghassan K. Abou-Alfa, MD, MBA**
Attending Gastrointestinal Oncology Service
Department of Medicine
Memorial Sloan Kettering Cancer Center

**Linda L. Wong, MD**
Associate Member, Cancer Biology
University of Hawaii Cancer Center Director, Liver Transplant Program
The Queen’s Medical Center

mskcc.org/APPLESTC2020
FACULTY

Ghassan Abou-Alfa, MD, MBA
Professor
Memorial Sloan Kettering Cancer Center
New York, NY, USA

Stephen Chan, MD
Associate Professor
Chinese University of Hong Kong
Hong Kong, China

Ann-Lii Cheng, MD, PhD
Professor
National Taiwan University
Taipei, Taiwan

Pierce Chow, MD, PhD
Professor
National Cancer Centre Singapore
Singapore, Singapore

Laura Dawson, MD
Professor
University of Toronto
Toronto, Ontario, Canada

Anthony El-Khoueiri, MD
Assistant Professor
University of Southern California
Los Angeles, CA, USA

Jospeh Erinjeri, MD, PhD
Associate Professor
Memorial Sloan Kettering Cancer Center
New York, NY, USA

Richard Finn, MD
Professor
University of California Los Angeles
Los Angeles, CA, USA

Peter Galle, MD, PhD
Professor
Mainz University
Mainz, Germany

Kwang-Hyub Han, MD, PhD
Professor
Yonsei University
Seoul, South Korea

Chih-Hung Hsu, MD, PhD
Professor
National Taiwan University
Taipei, Taiwan

Chiun Hsu, MD, PhD
Professor
National Taiwan University
Taipei, Taiwan

William Jarnagin, MD
Professor
Memorial Sloan Kettering Cancer Center
New York, NY, USA

Norihiro Kokudo, MD, PhD
President
National Center for Global Health and Medicine
Tokyo, Japan

Masatoshi Kudo, MD, PhD
Professor
Kindai University
Osaka, Japan

Irene Ng, MD
Professor
Hong Kong University
Hong Kong, China

Joong-Won Park, MD, PhD
Professor
National Cancer Center Korea
Seoul, South Korea

Riad Salem, MD, MBA
Professor
Northwestern University
Chicago, IL, USA

Bruno Sangro, MD, PhD
Professor
University of Navarra
Pamplona, Spain

Jinsil Seong, MD, PhD
Professor
Yonsei University
Seoul, South Korea

Augusto Villaneuva, MD, PhD
Assistant Professor
Mount Sinai Hospital
New York, NY, USA

Khin Maung Win, MD
Professor
Yangon General Hospital
Yangon, Maynamar

Jedd D. Wolchok, MD, PhD
Professor
Memorial Sloan Kettering Cancer Center
New York, NY, USA

Linda Wong, MD
Professor
University of Hawaii
Honolulu, HI, USA

Thomas Yau, MD
Assistant Professor
Hong Kong University
Hong Kong, China

Sheng-Long Ye, MD, PhD
Professor
Zhong Shan Hospital, Fudan University
Shanghai, China

Andrew Zhu, MD, PhD
Professor
Massachusetts General Hospital
Boston, MA, USA
## DAY 1 SCHEDULE

**New York**  
Friday, December 4 • 6:00-9:15 PM

**Honolulu**  
Friday, December 4 • 1:00-4:15 PM

**Beijing, Hong Kong, Singapore, & Taipei**  
Saturday, December 5 • 7:00-10:15 AM

**Seoul & Tokyo**  
Saturday, December 5 • 8:00-11:15 AM

---

All times listed below are New York Eastern Standard Time (EST). Please visit [thetimezoneconverter.com](http://thetimezoneconverter.com) to convert to your local time.

<table>
<thead>
<tr>
<th>Time</th>
<th>Session/Activity</th>
</tr>
</thead>
<tbody>
<tr>
<td>5:45 PM</td>
<td>DAY 1 VIRTUAL CHECK-IN</td>
</tr>
<tr>
<td>6:00 PM</td>
<td>Conference Welcome</td>
</tr>
<tr>
<td>6:05 PM</td>
<td>Conference Introduction</td>
</tr>
<tr>
<td>6:10 PM</td>
<td>Liver Basic Immunology</td>
</tr>
<tr>
<td>6:25 PM</td>
<td>HCC Genomics</td>
</tr>
<tr>
<td>6:40 PM</td>
<td>Surgical Impact</td>
</tr>
<tr>
<td>6:55 PM</td>
<td>Panel Discussion with Session Faculty</td>
</tr>
<tr>
<td>7:10 PM</td>
<td>BREAK</td>
</tr>
<tr>
<td>7:15 PM</td>
<td>Use of Checkpoint Inhibitors in Combination with Anti-VEGF and TKI</td>
</tr>
<tr>
<td>7:35 PM</td>
<td>Panel Discussion with Session Faculty</td>
</tr>
<tr>
<td>8:10 PM</td>
<td>BREAK</td>
</tr>
<tr>
<td>8:15 PM</td>
<td>Assessing Responders from Non-responders from Tumor Immune Microenvironment (TIME) Perspective</td>
</tr>
<tr>
<td>8:55 PM</td>
<td>Panel Discussion with Session Faculty</td>
</tr>
<tr>
<td>9:10 PM</td>
<td>Day 1 Closing Remarks</td>
</tr>
<tr>
<td>9:15 PM</td>
<td>DAY 1 ADJOURN</td>
</tr>
</tbody>
</table>

---

**Liver Immunology**  
CHAIRS: Kwang-Hyub Han, MD, PhD and Sheng-Long Ye, MD, PhD

<table>
<thead>
<tr>
<th>Time</th>
<th>Session/Activity</th>
</tr>
</thead>
<tbody>
<tr>
<td>6:10 PM</td>
<td>Liver Basic Immunology</td>
</tr>
<tr>
<td>6:25 PM</td>
<td>HCC Genomics</td>
</tr>
<tr>
<td>6:40 PM</td>
<td>Surgical Impact</td>
</tr>
<tr>
<td>6:55 PM</td>
<td>Panel Discussion with Session Faculty</td>
</tr>
<tr>
<td>7:10 PM</td>
<td>Use of Checkpoint Inhibitors in Combination with Anti-VEGF and TKI</td>
</tr>
<tr>
<td>7:55 PM</td>
<td>Panel Discussion with Session Faculty</td>
</tr>
</tbody>
</table>

**Use of Checkpoint Inhibitors in Combination with Anti-VEGF and TKI**  
CHAIRS: Masatoshi Kudo, MD, PhD and Richard Finn, MD

<table>
<thead>
<tr>
<th>Time</th>
<th>Session/Activity</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:15 PM</td>
<td>Combination of Checkpoint Inhibitors and Anti-VEGF</td>
</tr>
<tr>
<td>7:35 PM</td>
<td>Combination of Checkpoint Inhibitors and TKIs</td>
</tr>
<tr>
<td>7:55 PM</td>
<td>Panel Discussion with Session Faculty</td>
</tr>
</tbody>
</table>

**Assessing Responders from Non-responders from Tumor Immune Microenvironment (TIME) Perspective**  
CHAIRS: Linda L. Wong, MD and Joong-Won Park, MD, PhD

<table>
<thead>
<tr>
<th>Time</th>
<th>Session/Activity</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:15 PM</td>
<td>Tumor Markers Role</td>
</tr>
<tr>
<td>8:35 PM</td>
<td>Extracellular Vesicles and Particle Biomarkers</td>
</tr>
<tr>
<td>8:55 PM</td>
<td>Panel Discussion with Session Faculty</td>
</tr>
<tr>
<td>9:10 PM</td>
<td>Day 1 Closing Remarks</td>
</tr>
</tbody>
</table>

---

**Memorial Sloan Kettering Cancer Center**  
NEW YORK, NY

**University of Hawaii**  
HONOLULU, HI
## DAY 2 SCHEDULE

**New York**  
Saturday, December 5 • 6:00-9:15 PM

**Honolulu**  
Saturday, December 5 • 1:00-4:15 PM

**Beijing, Hong Kong, Singapore, & Taipei**  
Sunday, December 6 • 7:00-10:15 AM

**Seoul & Tokyo**  
Sunday, December 6 • 8:00-11:15 AM

---

All times listed below are New York Eastern Standard Time (EST).  
Please visit thetimezoneconverter.com to convert to your local time.

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>5:45 PM</td>
<td>DAY 2 VIRTUAL CHECK-IN</td>
<td></td>
</tr>
<tr>
<td>6:00 PM</td>
<td>Wrap up of day 1</td>
<td>Chih-Hung Hsu, MD, PhD</td>
</tr>
<tr>
<td>6:10 PM</td>
<td>KEYNOTE</td>
<td>Tumor Immune Microenvironment (TIME)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>CHAIRS: Ann-Lii Cheng, MD, PhD and Peter Galle, MD, PhD</td>
</tr>
<tr>
<td></td>
<td>Tumor Immune Microenvironment (TIME)</td>
<td>Jedd D. Wolchok, MD, PhD</td>
</tr>
<tr>
<td></td>
<td>Novel HCC Classification</td>
<td>Ghassan K. Abou-Alfa, MD, MBA</td>
</tr>
<tr>
<td></td>
<td>Panel Discussion with Session Faculty</td>
<td></td>
</tr>
<tr>
<td>6:50 PM</td>
<td>BREAK</td>
<td></td>
</tr>
<tr>
<td>7:10 PM</td>
<td>Role of Local Therapy in Tumor Immune Microenvironment (TIME), and Effect of Combination with Checkpoint Inhibitors</td>
<td></td>
</tr>
<tr>
<td></td>
<td>CHAIRS: Pierce Chow, MD, PhD and Laura Dawson, MD</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Role of Chemo and Bland Embolization</td>
<td>Joseph Erinjeri, MD</td>
</tr>
<tr>
<td></td>
<td>Role of Radio Embolization</td>
<td>Riad Salem, MD, MBA</td>
</tr>
<tr>
<td></td>
<td>Role of Radiation Therapy</td>
<td>Jinsil Seong, MD, PhD</td>
</tr>
<tr>
<td></td>
<td>Panel Discussion with Session Faculty</td>
<td></td>
</tr>
<tr>
<td>8:00 PM</td>
<td>BREAK</td>
<td></td>
</tr>
<tr>
<td>8:15 PM</td>
<td>Too Much to Too Little Anti-CTLA4</td>
<td></td>
</tr>
<tr>
<td></td>
<td>CHAIRS: Chiun Hsu, MD, PhD and Ghassan K. Abou-Alfa, MD, MBA</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Too Much Anti-CTLA4 is Needed</td>
<td>Thomas Yau, MD</td>
</tr>
<tr>
<td></td>
<td>Too Little Anti-CTLA4 is Enough</td>
<td>Bruno Sangro, MD, PhD</td>
</tr>
<tr>
<td></td>
<td>Panel Discussion with Session Faculty</td>
<td></td>
</tr>
<tr>
<td>8:50 PM</td>
<td>Closing Remarks</td>
<td>Ghassan K. Abou-Alfa, MD, MBA</td>
</tr>
<tr>
<td></td>
<td>Announcement of APPLE 2021</td>
<td>Khin Maung Win, MD</td>
</tr>
<tr>
<td>9:15 PM</td>
<td>DAY 2 ADJOURN</td>
<td></td>
</tr>
</tbody>
</table>
REGISTER ONLINE:
mskcc.org/APPLESTC2020

Registration Fees

Physicians (MDs, PhDs and DOs) $50
Advanced Practice Providers $25
Residents, Fellows, Nurses and Other Healthcare Providers $25
Industry Professionals* $85

*Industry professionals may attend MSK CME activities for their own education. Marketing, sales, and promotion of products and services is strictly prohibited at MSK CME activities.

Registration Discounts/Promotions

• MSK CME offers a discounted rate for MSK Alumni, MSK Cancer Alliance and Cancer Care Partners. If you are a member of one of these groups, please contact cme@mskcc.org for more information.
• MSK employee registration is complimentary. However, you must complete course registration in order to attend this course. If you are registered for this course and are unable to attend, please email cme@mskcc.org.

Accreditation

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Memorial Sloan Kettering Cancer Center and the Asia-Pacific Primary Liver Cancer Expert Association (APPLE). Memorial Sloan Kettering Cancer Center is accredited by the ACCME to provide continuing medical education for physicians.

AMA Credit Designation Statement
Memorial Sloan Kettering Cancer Center designates this live activity for a maximum of 5.00 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ABIM MOC Recognition Statement
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 5.00 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Faculty Disclosure
It is the policy of MSK to make every effort to insure balance, independence, objectivity, and scientific rigor in all continuing medical education activities which it provides as an ACCME accredited provider. In accordance with ACCME guidelines and standards, all faculty participating in an activity provided by MSK are expected to disclose any significant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services which are discussed by the faculty members in an educational presentation. As required by the ACCME, when an unlabeled use of a commercial product or an investigational use not yet approved for any purpose is discussed during an educational activity, MSK requires the speaker to disclose that the product is not labeled for the use under discussion or that the product is still investigational.